ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 909

Diagnostic Autoantibody Signatures Of Rheumatoid Arthritis Patients Identified With a Bead-Based Assay Approach

Angelika Lueking1, Petra Budde1, Stefan Vordenbäumen2, Carmen Theek1, Heike Goehler1, Martin Gamer1, Peter Schulz-Knappe1 and Matthias Schneider3, 1Protagen AG, Dortmund, Germany, 2Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, 3Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cells in Human and Animal Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease typically characterized by chronic inflammation, accumulation of self-reactive B-cells and production of autoantibodies of which anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) have diagnostic utility. 30% of RA patients remain sero-negative making the early diagnosis of RA more difficult. Our goal is to develop a novel autoantibody-based diagnostic test that allows to correctly diagnosing CCP-negative early RA patients.

Methods: We performed a large-scale screen of 5800 proteins in a total of 250 serum samples of patients with stable RA, patients with SLE and healthy volunteers. An automated bead-based Luminex xMAP technology enables to measure the reactivity of autoantibodies to up to 500 different antigens in one single serum sample. All proteins are produced from E.coli, are highly purified by affinity capturing, sequenced by mass spectrometry, and each protein is coupled in optimized concentration to individual color coded Luminex beads. Biostatistical analysis was performed using univariate as well as multivariate statistical algorithms.

Results: 144 novel antigens were identified in RA patients. The autoantibody profile of RA patients is heterogeneous with some overlap between CCP-positive and CCP-negative patients. We therefore evaluated panels comprising five to ten antigens for identification of CCP-negative RA patients. One panel with six antigens showed a specificity comparable to CCP in CCP-negative patients. Another panel was able to detect about 60% of CCP-negative. Comparison to an active control group consisting of 100 SLE patients, an AUC was obtained of 0.78, with high a specificity of 0.86 and a lower sensitivity of 0.54.

Conclusion: CCP-negative RA patients can be identified based on specific set of autoantibodies. Further studies are currently conducted to validate the biomarker panels in early RA patients.


Disclosure:

A. Lueking,

Protagen ,

3;

P. Budde,

Protagen,

3;

S. Vordenbäumen,
None;

C. Theek,

Protagen,

3;

H. Goehler,

Protagen,

3;

M. Gamer,

Protagen,

3;

P. Schulz-Knappe,

Protagen,

6;

M. Schneider,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-autoantibody-signatures-of-rheumatoid-arthritis-patients-identified-with-a-bead-based-assay-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology